The FDA today will meet with several companies who make bile duct stents. At issue will be the pervasive off-label use of the biliary stents in large arteries, such as the ones leading to kidneys and legs. Some manufacturers express concern that the meeting could lead to a slowing of approvals or more rigorous pre-market testing of the devices by the FDA.

Related Summaries